Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study

Autor:	Tomoki Hori, Kazuhiro Yamamoto, Takefumi Ito, Shigeki Ikushima, Tomohiro Omura, Ikuko Yano
Rok vydání:	2023
Předmět:	Pharmacology Pharmaceutical Science General Medicine
Zdroj:	Biological and Pharmaceutical Bulletin. 46:788-795
ISSN:	1347-5215 0918-6158
DOI:	10.1248/bpb.b22-00794
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::72693ba9becb3bcf61c3c3af5f6c52a3 https://doi.org/10.1248/bpb.b22-00794 Zobrazit plný text záznamu